Orange Grove Bio
Orange Grove Bio is a Cincinnati-based biotech company-creation platform that sources academic research from underserved U.S. regions and abroad, forms majority-owned subsidiaries around licensed IP, and develops preclinical therapeutics in oncology, autoimmune, inflammatory, fibrotic, and rare genetic diseases for eventual pharma partnership or acquisition.
- Company typePrivate
- Founded2019
- HeadquartersCincinnati, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Orange Grove Bio does
Orange Grove Bio (legal entity Orange Grove Bio LLC, also referenced as OGB) is a private, Cincinnati-based biotech holding and company-creation platform founded in 2019. The firm identifies promising early-stage academic research from U.S. regions underserved by traditional venture capital — specifically the Southeast, Midwest, and Mid-Atlantic — as well as from South Korea and Israel, and forms majority-owned subsidiaries that license in foundational intellectual property from those universities. Its portfolio of six disclosed companies (five active) spans small-molecule immunoproteasome inhibitors (IpiNovyx Bio), TGF-beta pathway modulators for fibrosis (DomainOne Therapeutics), non-viral gene therapy for cystic fibrosis (Genexys BioMed), small molecules for inflammatory bowel disease and metabolic disease (Allonix Therapeutics), ex vivo platelet preservation additives (Preservation Bio), and neutrophil-targeted drug delivery for inflammatory disease (Asalyxa Bio).
The operating model combines in-house drug-development capabilities — including medicinal chemistry, CMC, translational biology, regulatory affairs, and venture operations — with academic sourcing relationships. Orange Grove Bio provides both scientific and financial support to portfolio entities, which retain the licensed IP, and positions them for licensing, co-development, or acquisition by pharmaceutical partners. The platform has secured notable non-dilutive capital for portfolio companies, including a $2.05 million NIH SBIR Phase II grant for Preservation Bio and a $320,000 Phase I SBIR for Genexys BioMed, alongside strategic equity rounds (IpiNovyx's $10M seed led by Viva BioInnovator with Eli Lilly participation). Strategic partnerships with institutions such as the University of Chicago, University of Pittsburgh, Dartmouth, Einstein, Weizmann/Bina, Yonsei, and POSTECH extend the sourcing network.
Orange Grove Bio monetizes through equity ownership in portfolio companies and milestone economics tied to licensing, co-development, or acquisition transactions with pharmaceutical companies, rather than direct product sales. It has raised a 2025 round from a Denver-based investor consortium and operates with 11-50 employees under a leadership team including CEO Salvatore Cremona (appointed August 2025), President & General Counsel Garin Murphy, and CFO David Crampton. All portfolio programs remain preclinical, with IpiNovyx targeting clinical entry around mid-2026.
Orange Grove Bio firmographics
Firmographics- Name
- Orange Grove Bio
- Legal name
- Orange Grove Bio LLC
- Website
- https://orangegrovebio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Orange Grove Bio is a Cincinnati-based biotech company-creation platform that sources academic research from underserved U.S. regions and abroad, forms majority-owned subsidiaries around licensed IP, and develops preclinical therapeutics in oncology, autoimmune, inflammatory, fibrotic, and rare genetic diseases for eventual pharma partnership or acquisition.
- Ownership category
- akta.pro rank
Orange Grove Bio industry classification
Industry- Product category
- Preclinical Drug Development and Biotech Investment Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where Orange Grove Bio is headquartered
LocationHeadquarters
- HQ city
- Cincinnati
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Orange Grove Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Company Creation and Equity Ownership: Orange Grove Bio creates new biotech companies from academic research, retaining equity ownership. The company generates returns when portfolio companies are acquired, go public, or achieve milestones through partnerships with pharmaceutical companies.
- Strategic Partnerships with Pharma: Partnerships with pharmaceutical companies for co-development, licensing, and commercialization of therapeutic candidates developed through the platform.
- NIH Grant Funding: Portfolio companies receive NIH SBIR grants to advance specific technologies (e.g., Preservation Bio's $2.05M SBIR Phase II grant, Genexys BioMed's $320K Phase 1 SBIR grant).
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Orange Grove Bio product offering
Product offeringCore offering
Orange Grove Bio is a preclinical drug investment and development platform that identifies promising academic research in non-traditional venture capital regions (Southeast, Midwest, Mid-Atlantic) and creates majority-owned biotech portfolio companies to advance those discoveries toward clinical development. The company then partners with or sells those portfolio companies to pharmaceutical companies, retaining equity and earning returns via licensing, milestones, and exits.
Product overview
Orange Grove Bio is a biotech holding company and company creation platform that identifies, invests in, and develops early-stage therapeutic candidates. The platform operates across five therapeutic focus areas: oncology, autoimmune diseases, inflammatory diseases, fibrosis, and rare genetic disorders. The company has launched seven portfolio companies including Allonix Therapeutics (small molecules for IBD/metabolic disease), DomainOne Therapeutics (TGF-beta inhibitors for fibrosis), Genexys BioMed (non-viral gene therapy for cystic fibrosis), IpiNovyx Bio (proteasome inhibitors for autoimmune/inflammatory diseases), Preservation Bio (platelet preservation additives for transfusion medicine), and Asalyxa Bio (neutrophil-targeted drug delivery). Orange Grove Bio provides scientific expertise, financial support, and operational capabilities to translate discoveries from academic research into clinical-stage therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- IpiNovyx Bio Pre-clinical stage biopharmaceutical company (majority-owned portfolio company) developing next-generation, highly selective reversible small molecule inhibitors of the immunoproteasome for the treatment of oncology, autoimmune, and inflammatory diseases. Lead program targeted at clinical entry mid-2026.
- Preservation Bio Pre-clinical stage company (majority-owned portfolio company) developing an ex vivo platelet additive that protects platelets from cold storage damage, extends shelf life from 5-7 days to 14 days under refrigeration, reduces bacterial contamination risk, and addresses platelet shortage in the blood supply chain.
- Genexys BioMed Pre-clinical stage company (majority-owned portfolio company) developing a novel non-viral, non-lipid gene therapy platform for cystic fibrosis treatment. Delivers therapeutic mRNA/DNA directly to patient lungs using organic polymer-based technology, designed to work for all CF patients regardless of CFTR mutation.
- Allonix Therapeutics Pre-clinical stage company (majority-owned portfolio company) developing novel small molecule drugs that target a cell-signaling pathway implicated in inflammation, cholesterol homeostasis, and cellular metabolism. Lead program aims to treat inflammatory bowel disease (IBD) through a unique mechanism of action, with pipeline potential for diabetes, obesity, and cancers.
- DomainOne Therapeutics Pre-clinical stage company (majority-owned portfolio company) developing small molecule inhibitors modulating the TGF-beta pathway to treat fibrosis. Initial focus on fibrotic diseases affecting liver, lungs, heart, and kidneys by targeting thrombospondin 1 (TSP1) Domain One to inhibit TGF-beta activation.
- Asalyxa Bio First portfolio company (now inactive) developing nano-engineered, immune cell-targeted therapeutics using the PANTHER platform. Lead program ASX-100 delivered anti-inflammatory agents directly to overreactive neutrophils for treatment of Acute Respiratory Distress Syndrome (ARDS) and inflammatory diseases.
Quantifiable outcome
- Extended platelet shelf life from 5-7 days to 14 days, potentially reducing 10-15% platelet waste
- +2 more outcomes
Companies that use Orange Grove Bio
Customer profileSegments2 records
Ideal customer profiles2 records
Orange Grove Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Orange Grove Bio partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and minor.
- University of Chicago (Polsky Center)coreStrategic partnership to catalyze commercialization of novel therapeutics and life sciences technologies. Orange Grove will license promising technologies from UChicago and establish presence on South Side of Chicago.
- Yonsei University Health SystemcorePartnership to strengthen biotech entrepreneurial ecosystem in South Korea. Orange Grove will support translation of scientific discoveries and company creation in oncology and autoimmune/inflammatory diseases.
- Pohang University of Science and Technology (POSTECH)corePartnership to strengthen biotech entrepreneurial ecosystem in South Korea through educational programming and company creation support in oncology and autoimmune/inflammatory diseases.
- Weizmann Institute of Science (Bina)coreCollaboration with Bina, the translational research unit of Weizmann Institute, to tap into the biotech ecosystem in the Middle East. Orange Grove will guide and mentor early-stage research, identify opportunities for company creation, and implement graduate internship programs.
- Dartmouth College (Magnuson Center)coreCollaboration to strengthen biotech ecosystem and support commercialization of novel therapeutics. Includes PhD internship program and Orange Grove team serving as Entrepreneur in Residence.
- University of PittsburghcoreCollaboration to advance development and commercialization of novel therapeutics by supporting translation of discoveries in oncology and autoimmune/inflammatory diseases. Includes PhD internships for Pitt students.
- Albert Einstein College of MedicinecorePartnership with Einstein, AlleyCorp, and Alexandria Venture Investments to support development of novel therapeutics. Einstein scientists receive mentorship and financial support to advance research into new drug candidates.
- Crohn's & Colitis FoundationcorePartnership with Crohn's & Colitis Foundation for Allonix Therapeutics, the leading non-profit organization in IBD space. The Foundation's IBD Ventures group has invested in Allonix.
- Cincinnati Children's Hospital Medical CentercoreSource of multiple technologies including Genexys BioMed's gene therapy platform and Preservation Bio's platelet storage technology. Dr. Assem Ziady's lab at Cincinnati Children's developed the gene therapy technology.
- University of CincinnaticoreSource of Preservation Bio's platelet storage technology. Dr. Jose Cancelas and Dr. Yi Zheng led research at University of Cincinnati and Cincinnati Children's Hospital Medical Center.
- University of AlabamacoreSource of DomainOne Therapeutics' TGF-beta inhibitor technology, developed in partnership with Southern Research Institute.
- Southern Research InstitutecorePartner in DomainOne Therapeutics alongside University of Alabama for development of TGF-beta pathway inhibitors for fibrosis treatment.
- Weill Cornell MedicinecoreSource of IpiNovyx Bio's proteasome inhibitor technology from labs of Gang Lin and Carl Nathan at Weill Cornell Medicine.
- Hospital for Special Surgery Research InstitutecoreSource of IpiNovyx Bio's technology from lab of Franck Barrat at Hospital for Special Surgery Research Institute.
- Emory UniversitycoreSource of Allonix Therapeutics' foundational science from pioneering work by Eric Ortlund and Dr. John Calvert at Emory University.
- Hoxworth Blood CenterminorClinical trial site for Preservation Bio's Phase 1 clinical trial in Cincinnati.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
Orange Grove Bio competitors and assessment
Company assessmentDirect peers
- Roivant Sciences: Largest biotech company-creation platform; launches and incubates subsidiary biotechs (Vants) around specific therapeutic assets and exits via pharma partnerships or spinouts — the closest operational analogue to Orange Grove Bio's model.
- PureTech Health: Clinical-stage biotherapeutics company creation platform that identifies academic discoveries and develops them through majority-owned subsidiaries — closely matches Orange Grove Bio's holding-company structure and academic-sourcing strategy.
- BridgeBio Pharma: Biotech that builds subsidiaries around genetically validated disease targets sourced from academic research; comparable in building multiple parallel programs with pharma partnership as a key exit vector.
- Apple Tree Partners: Biotech venture capital firm that both finances and builds biotech companies around academic and emerging biopharma assets — closely mirrors Orange Grove Bio's build-and-partner model.
- Atlas Venture: Early-stage biotech venture firm that forms and incubates new companies from academic science with experienced pharma operators; comparable in building and seeding preclinical biotechs.
Broad incumbents
- Flagship Pioneering: Largest biotech platform creating companies from scientific concepts; similar company-creation model with much greater scale and capital base (founded Moderna, Generate Biomedicines).
- Deerfield Management: Healthcare-focused investment firm with significant academic partnership and company-creation capabilities across therapeutics; broader scale and capital than Orange Grove Bio but overlapping sourcing model.
Emerging players
- Cedilla Therapeutics (now part of Lilly): Pre-clinical biotech focused on targeted protein degradation, originated from academic science at Princeton — illustrates the academic-sourcing and pharma-exit pathway Orange Grove Bio pursues for its portfolio.
- Aiolos Bio: Biotech developing small molecule therapeutics for inflammatory diseases (similar to Allonix's IBD focus) — comparable as a portfolio-company-scale asset within a similar sourcing and development model.
Others
- Asalyxa Bio: Orange Grove Bio's own first portfolio company developing neutrophil-targeted therapeutics for ARDS/inflammation — included to illustrate the type of spinout the platform creates rather than as an external competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Orange Grove Bio social profiles
Digital presenceOrange Grove Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Orange Grove Bio leadership team
Management profileNumber of profiles
Profiles14 records
Orange Grove Bio subsidiaries and ownership
Company hierarchySubsidiaries5 records
Orange Grove Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Orange Grove Bio M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Orange Grove Bio
What does Orange Grove Bio do?
Orange Grove Bio is a preclinical drug investment and development platform that identifies promising academic research in non-traditional venture capital regions (Southeast, Midwest, Mid-Atlantic) and creates majority-owned biotech portfolio companies to advance those discoveries toward clinical development. The company then partners with or sells those portfolio companies to pharmaceutical companies, retaining equity and earning returns via licensing, milestones, and exits.
Is Orange Grove Bio a public or private company?
Orange Grove Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Orange Grove Bio founded?
Orange Grove Bio was founded in 2019. It employs 11 to 50 people.
Where is Orange Grove Bio based?
Orange Grove Bio is headquartered in Cincinnati, United States, in the North America region.
How does Orange Grove Bio make money?
Three revenue lines are on record. Company Creation and Equity Ownership is the primary driver. The others are strategic Partnerships with Pharma and NIH Grant Funding.
Who are Orange Grove Bio's main competitors?
Direct peers on record are Roivant Sciences, PureTech Health, BridgeBio Pharma, Apple Tree Partners and Atlas Venture. Broad incumbents are Flagship Pioneering and Deerfield Management. Emerging players are Cedilla Therapeutics (now part of Lilly) and Aiolos Bio. Asalyxa Bio is listed as an others.
Does Orange Grove Bio have an API?
No public API is recorded for Orange Grove Bio.
What industry is Orange Grove Bio in?
Orange Grove Bio's product category is Preclinical Drug Development and Biotech Investment Platform. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 541714 and its SIC code is 8731.